Frequencies for first 10,000 rows of lit_ref variable in demo2015q1 dataset : Literature Reference | Freq. Percent Cum. ----------------------------------------+----------------------------------- | 9,484 94.84 94.84 , BARRETO S, SINGH A, BATRA S, MITTRA.. | 1 0.01 94.85 , BATCHELOR T, LI S, HOCHBERG E, BREZ.. | 1 0.01 94.86 , BERRY J, YU H AND CUDKOWICZ M. SAFE.. | 1 0.01 94.87 , BONDANZA A, OLIVEIRA M, BADOGLIO M,.. | 1 0.01 94.88 , CANNITA K, ADINOLFI M, BROLLO M, SA.. | 1 0.01 94.89 , CHARLES J, PINEL N, CHALLENDE I, CL.. | 1 0.01 94.90 , CHARLES J, PINEL N, CHALLENDE I, CL.. | 1 0.01 94.91 , CHELIS L, CHAMALIDOU H, MICHAILIDIS.. | 1 0.01 94.92 , CHRISTIAN B, JAGLOWSKI S, FLYNN J, .. | 1 0.01 94.93 , CONTE H, JOUARY T, FAUCONNEAU A, DA.. | 1 0.01 94.94 , CONTE H, JOUARY T, FAUCONNEAU A, DA.. | 1 0.01 94.95 , CONTE H, JOUARY T, FAUCONNEAU A, DA.. | 1 0.01 94.96 , ELSTROM R AND BUSSEL J THE COMBINAT.. | 1 0.01 94.97 , FJETLAND L, KURZ K, ROY S. AND KURZ.. | 1 0.01 94.98 , FJETLAND L, KURZ K, ROY S. AND KURZ.. | 1 0.01 94.99 , FOWLER, N. WAGNER, B. HAGEMEISTEER .. | 1 0.01 95.00 , FRANKEL P, POPPLEWELL L, SIDDIQI T,.. | 1 0.01 95.01 , GUILLEVIN L RITUXIMAB OR AZATHIOPRI.. | 1 0.01 95.02 , IASONOS A, ZHOU Q, DURANY R, AGHAJA.. | 1 0.01 95.03 , JANUS N, SELLE F, GOLDWASSER F, MIR.. | 1 0.01 95.04 , KENTEPOZIDIS N, CHRISTOPHYLLAKIS C,.. | 1 0.01 95.05 , KIM J, KIM J, JANG J, KIM C AND CHO.. | 1 0.01 95.06 , KURZ K, ROY S. AND KURZ M. EVALUATI.. | 2 0.02 95.08 , KURZ K, ROY S. AND KURZ M. EVALUATI.. | 1 0.01 95.09 , LAMANNA N, KIPPS T, FLINN I, ZELENE.. | 1 0.01 95.10 , LEACH J, TSAI M, FORAN J, FORERO A,.. | 1 0.01 95.11 , MANSO L, SAENZ J, CIRUELOS E, MOREN.. | 1 0.01 95.12 , MARRODAN, I. CALVO, B. MUNOZ, A. MA.. | 1 0.01 95.13 , MARTEL-LAFERRIERE V, BICHOUPAN K, S.. | 1 0.01 95.14 , MATIAS G. CALADO S. ALEGRIA C. LOUR.. | 1 0.01 95.15 , MULDER K, GHOSH S AND SPRATLIN J. R.. | 1 0.01 95.16 , NAGEL W, HERZ S, WESSLING G, LEPIQU.. | 1 0.01 95.17 , OZBILIM G. TUBERCULOSIS LYMPHADENIT.. | 1 0.01 95.18 , PERALTA R, VIANA P, MORGADO C, MELO.. | 1 0.01 95.19 , QIN R, PITOT H, PICUS J, LIU G, FIT.. | 1 0.01 95.20 , REED G, KARKI C, MAGNER R, SHEWADE .. | 1 0.01 95.21 , ROJAS-HERNANDEZ C, FEKRAZAD M, STEI.. | 1 0.01 95.22 , SCHUSTER C, AKSLEN L. AND STRAUME O.. | 1 0.01 95.23 , SCHWARTZBERG L, RIVERA F, FASOLA G,.. | 1 0.01 95.24 , SHARMA K, CLAXTON D, EHMANN C, SHIM.. | 1 0.01 95.25 , SHIGEFUKU RYUTA, TAKAHASHI HIDEAKI,.. | 1 0.01 95.26 , SHIMADA M, NISHINA T, MORIWAKI T, O.. | 1 0.01 95.27 , SORENSEN J, HOEFFKEN G, FAVARETTO A.. | 1 0.01 95.28 , SWINNEN L, WIERDA W, JONES J, COUTR.. | 1 0.01 95.29 , VAN DER MEER A, HANSEN B, FELD J , .. | 1 0.01 95.30 , VASILYEV V, SAFONOVA T, RODIONOVA E.. | 1 0.01 95.31 , WAGNER-JOHNSTON N; COUTRE, STEVEN E.. | 1 0.01 95.32 , WALEWSKI J, DOHNER H, VIARDOT A, HI.. | 1 0.01 95.33 , YING G, HUANG J, LEVY N AND MAGUIRE.. | 1 0.01 95.34 , YING G, HUANG J, LEVY N AND MAGUIRE.. | 1 0.01 95.35 . COMBINATION BIOLOGIC THERAPY WITHOU.. | 1 0.01 95.36 . DUALNA BLOKADA HER2 RECEPTORA: VPLY.. | 1 0.01 95.37 ?????,?????,??????,?????,?????,??????.. | 1 0.01 95.38 A CASE OF ACUTE INTERSTITIAL PNEUMONI.. | 1 0.01 95.39 A RETROSPECTIVE STUDY OF 13 PATIENTS .. | 1 0.01 95.40 A SUZUKI. A CASE OF CONTAGIOUS IMPETI.. | 1 0.01 95.41 AABIDEEN K, MOULTON LS, SILLS J. ACCI.. | 1 0.01 95.42 ABE T, TAKEDA K, OHE Y, KUDOH S, ICHI.. | 1 0.01 95.43 ACQUISTAPACE G, ROSSI M, GARBI M, COS.. | 1 0.01 95.44 ACQUISTAPACE G, ROSSI M, GARBI M, COS.. | 2 0.02 95.46 ACQUISTAPACE G, ROSSI M, GARBI M, COS.. | 2 0.02 95.48 ACQUISTAPACE G,ROSSI M,GARBI M,COSCI .. | 1 0.01 95.49 ACQUISTAPACE G,ROSSI M,GARBI M,COSCI .. | 1 0.01 95.50 ADELMAN LC, MCGILLICUDDY DC.. ENOXAPA.. | 1 0.01 95.51 AGGARWAL N, KUPFER Y, SENEVIRATNE C, .. | 1 0.01 95.52 AHMAD S,SCOLNIK D,SNEHAL V,GLATSTEIN .. | 1 0.01 95.53 AKBAL E, BATGI H, KOCAK E, CANATAN T,.. | 1 0.01 95.54 AKIHIRO NISHIYAMA ET AL.. A CASE OF D.. | 1 0.01 95.55 AL-SALEH S, AL-NAIMI A. HAMILTON J, Z.. | 1 0.01 95.56 AL-SALEH S, AL-NAIMI, A. HAMILTON, J... | 1 0.01 95.57 ALEXEEVA E, BARANOV A, DENISOVA R, VA.. | 1 0.01 95.58 ALMENARA MC, BLANCO IV, CASAFONT F, E.. | 1 0.01 95.59 ALVES MF, PITTA MDL, PERES M, LEAL M,.. | 1 0.01 95.60 ANA MONTALVAO,. USE OF BORTEZOMIB (VE.. | 1 0.01 95.61 ANDERSEN JDH, LAURITSEN AO. LITHIUM I.. | 1 0.01 95.62 ANDERSON M. THE MANAGEMENT OF POISONI.. | 1 0.01 95.63 ANDRADE C..THE SAFETY OF DULOXETINE D.. | 1 0.01 95.64 ANDRIEU E, AL SAIF F, DUVAL MODESTE A.. | 1 0.01 95.65 ANNE ROBINS,ABUL AZIM,MARTYN PATEL. A.. | 1 0.01 95.66 AOKI TAKU, ET AL.. MULTIDISCIPLINARY .. | 1 0.01 95.67 AOUAM K, BOUIDA W, BEN FREDJ N, CHAAB.. | 1 0.01 95.68 ARAOKA H. ONSET OF PULMONARY MUCORMYC.. | 1 0.01 95.69 AUGUSTIN P, DESMARD M, ARAPIS K, FOUR.. | 1 0.01 95.70 AURLIEN D ET AL. LAMOTRIGINE IN IDIOP.. | 1 0.01 95.71 AZAR, N. J.. ACUTE PANCREATITIS AND E.. | 1 0.01 95.72 BANSAL S, GUPTA SK. SODIUM VALPROATE .. | 1 0.01 95.73 BAWOLAK MT, DJELOUAH I. MINOCYCLINE: .. | 1 0.01 95.74 BAWOLAK MT, DJELOUAH I. MINOCYCLINE: .. | 1 0.01 95.75 BEATTY NC, NICHOLSON WT, LANGMAN LJ, .. | 1 0.01 95.76 BECK-SCHIMMER B, BONVINI J, SCHADDE E.. | 1 0.01 95.77 BECK-SCHIMMER B, BREITENSTEIN S, BONV.. | 1 0.01 95.78 BELLANTUONO C, BOZZI F, ORSOLINI L. S.. | 1 0.01 95.79 BERENT D, GALECKI P. PSYCHOPHARMACOLO.. | 1 0.01 95.80 BERG, J.. INTRACTABLE SCHIZO-AFFECTIV.. | 1 0.01 95.81 BIRNBAUM G, IVERSON J. DALFAMPRIDINE .. | 2 0.02 95.83 BLAIS, NORMAND. SUNITINIB COMBINED WI.. | 1 0.01 95.84 BORREGO-UTIEL FJ, P?REZ-DEL BARRIO MD.. | 1 0.01 95.85 BOTTIEAU E, VERBRUGGEN E, AUBRY C, SO.. | 1 0.01 95.86 BOTTIGLIERI S, TIERSON N, PATEL R, MO.. | 1 0.01 95.87 BREITENSTEIN S, BONVINI J, SCHADDE E,.. | 5 0.05 95.92 BRONSTEIN, A.. 2011 ANNUAL REPORT OF .. | 1 0.01 95.93 BROWN A, HOELZER D, PIERCY S. SKIN NE.. | 1 0.01 95.94 BUSH NC, TWOMBLEY K, AHN J, OLIVEIRA .. | 1 0.01 95.95 CADUFF F, GLOOR HJ. HYDROCHLOROTHIAZI.. | 1 0.01 95.96 CAIMMI D, CAIMMI S, AMICI MD, BOSA L,.. | 1 0.01 95.97 CAPARELLO C, LOUPAKIS F, SCHIRRIPA M,.. | 1 0.01 95.98 CARABELLESE F, CANDELLI C, LA TEGOLA .. | 1 0.01 95.99 CASANOVA M, CHAPARRO M, VALENZUELA C,.. | 1 0.01 96.00 CEREBRAL INFARCTION COMPLICATED BY LA.. | 1 0.01 96.01 CHAHIN S AND BERGER JR. A RISK CLASS.. | 1 0.01 96.02 CHAN JCW, LI KKW. CAN CONSTIPATION LE.. | 1 0.01 96.03 CHERUVU, C. SUCCESSFUL ABLATION OF IN.. | 1 0.01 96.04 CHOUDHARY SV, MADNANI A, SINGH AL.. L.. | 1 0.01 96.05 CIGARRAN S, RODRIGUEZ ML, POUSA M, ME.. | 1 0.01 96.06 COBAN-KARATAS M, TURUNC T, ALTAN-YAYC.. | 1 0.01 96.07 CONWAY K, WILLIAMS D, QUIN J, DEAN G,.. | 1 0.01 96.08 CONWAY K, WILLIAMS D, QUIN J, DEAN G,.. | 2 0.02 96.10 CORDEIRO I, PERALTA R, BENTES C. CLON.. | 1 0.01 96.11 COREY A. FIRST DO NO HARM: A CASE OF .. | 1 0.01 96.12 CORTES JA, RADHAKRISHNAN R.. A CASE O.. | 1 0.01 96.13 CROSBY D, PETERSON J, CARROLL BT.. AT.. | 1 0.01 96.14 CULLINGTON D, DUNFORD N, BEER S, HOBS.. | 1 0.01 96.15 CUSACK C, NIJHAWAN R, MILLER B, HENIE.. | 1 0.01 96.16 DALLA COSTA G, COLOMBO B, DALLA LIBER.. | 1 0.01 96.17 DANG D, WANG D, ZHANG C, ZHOU W, ZHOU.. | 1 0.01 96.18 DE RAAD A W, SIEGERSMA N C, CLAHSEN E.. | 1 0.01 96.19 DE-GIORGIO F, LODISE M, CHIAROTTI M, .. | 1 0.01 96.20 DEMIR E.Y, SAYIN A.. A PATIENT WITH P.. | 1 0.01 96.21 DER-YUAN C, HSEIH C, CHEN D, LEE B AN.. | 1 0.01 96.22 DILL P, DATTA AN, WEBER P, SCHNEIDER .. | 1 0.01 96.23 DR. Y. NAKAFUSA. A REVIEW OF CHEMOTHE.. | 1 0.01 96.24 D^URZO A,KERWIN E,RENNARD S,HE T,GARC.. | 1 0.01 96.25 EGUCHI K ET AL. AN ADVERSE PREGNANCY-.. | 1 0.01 96.26 EGUCHI K ET AL.,. AN ADVERSE PREGNANC.. | 1 0.01 96.27 EIPE, N. POSTOPERATIVE RESPIRATORY DE.. | 1 0.01 96.28 EIPE, N.. POSTOPERATIVE RESPIRATORY D.. | 1 0.01 96.29 EIPE, N.. POSTOPERATIVE RESPIRATORY D.. | 1 0.01 96.30 EKELUND K., FOLSGAARD S. LACTIC ACIDO.. | 1 0.01 96.31 ELNADOURY O,YUEN M,OH E,ABRAHAM T,SAA.. | 1 0.01 96.32 EZEJI, G. C.. HALLUCINATIONS ASSOCIAT.. | 1 0.01 96.33 EZOE Y, MUTO M, UEDA K, OZAKI Y, AOYA.. | 1 0.01 96.34 FAILLIE JL, PINZANI V, JACQUEMOIRE J,.. | 1 0.01 96.35 FALCON-CANTRILL M., SALDIVAR R., ASSA.. | 1 0.01 96.36 FALTAS B, KAUR G, AKHTAR N, CHRISTOS .. | 1 0.01 96.37 FERNANDEZ-ATUTXA A, VERGARA M, GIL M,.. | 1 0.01 96.38 FERNANDO SL, HUDSON BJ. RAPID DESENSI.. | 1 0.01 96.39 FERRANDIZ-PULIDO C, GARCIA-FERNANDEZ .. | 1 0.01 96.40 FERRARI S, RUGGIERI P, CEFALO G, TAMB.. | 1 0.01 96.41 FERRARI S, RUGGIERI P, CEFALO G, TAMB.. | 1 0.01 96.42 FINE, A. J., SORBELLO, A., KORTEPETER.. | 1 0.01 96.43 FISHER AA, BASSETT ML. ACUTE PANCREAT.. | 1 0.01 96.44 FLINN IW, VAN DER JAGT RH, KAHL BS, W.. | 1 0.01 96.45 FLINN IW, VAN DER JAGT RH, KAHL BS, W.. | 1 0.01 96.46 FOGERTY, R.L. FATAL INTRACRANIAL HEMO.. | 1 0.01 96.47 FONG PH, WOO KT, CHAN HL, CHIANG G. A.. | 1 0.01 96.48 FONTANA RJ, ELLERBE C, DURKALSKI VE, .. | 1 0.01 96.49 FORTINSKY KJ, ALALI A, JEEJEEBHOY K, .. | 1 0.01 96.50 FREYER M, VACHALOVA I, ZIRNGIBL B AND.. | 1 0.01 96.51 FROL S. NOVEJSA ANTIKOAGULANTNA ZDRAV.. | 1 0.01 96.52 FUKAMATSU H. DRUG-INDUCED SKIN DISORD.. | 1 0.01 96.53 GARCIA SANCHEZ VC, CALLE ROMERO Y, DE.. | 1 0.01 96.54 GARERI P., SEGURA-GARCIA C., DE FAZIO.. | 1 0.01 96.55 GARY BIRNBAUM, JANE E. IVERSON. DALFA.. | 1 0.01 96.56 GELLER R, HUNTINGTON S, KEZIRIAN R, A.. | 1 0.01 96.57 GEREVINI S, CALIENDO G, CAVA M, CAPRA.. | 2 0.02 96.59 GEREVINI S, CALIENDO G, CAVA M, CAPRA.. | 1 0.01 96.60 GEREVINI S, CALIENDO G, CAVA M, CAPRA.. | 1 0.01 96.61 GEREVINI S, CALIENDO G, CAVA M, CAPRA.. | 1 0.01 96.62 GEREVINI S, CALIENDO G, CAVA M, CAPRA.. | 1 0.01 96.63 GISONDI P, ROMANO I, SASSO E, GUADAGN.. | 1 0.01 96.64 GORDON M, ROBERT F, MATEI D, MENDELSO.. | 1 0.01 96.65 GRAY JA. PARKINSONISM AND RABBIT SYND.. | 1 0.01 96.66 GROSSET-JANIN C. A RETROSPECTIVE STUD.. | 1 0.01 96.67 GROTTOLI S.. ACROSTUDY: THE ITALIAN E.. | 1 0.01 96.68 GROTTOLI S.. ACROSTUDY: THE ITALIAN E.. | 1 0.01 96.69 H?KKINEN MARGAREETA. PROFILES OF PREG.. | 1 0.01 96.70 HABEICHI W, AHMED G.. A CASE OF SEVER.. | 1 0.01 96.71 HAMMOND KP, NIELSEN C, LINNEBUR SA, L.. | 1 0.01 96.72 HANDA T, NAKATSUE T, BABA M, TAKADA T.. | 1 0.01 96.73 HANTSON P, BATISTA M, FONSECA S, FERR.. | 1 0.01 96.74 HANTSON P, BATISTA M, FONSECA S, FERR.. | 1 0.01 96.75 HANTSON. ACUTE HEART FAILURE AFTER VE.. | 1 0.01 96.76 HASTIER P, BUCKLEY MJ, PETEN EP, DEMU.. | 2 0.02 96.78 HASTIER P, BUCKLEY MJ, PETEN EP, DEMU.. | 2 0.02 96.80 HAUVILLIER L, EYVRARD F, GARNAULT V, .. | 1 0.01 96.81 HAYAMA, M.. STUDY ON CRIZOTINIB ADMIN.. | 1 0.01 96.82 HEAPS T. PROBLEM-BASED REVIEW: PARACE.. | 1 0.01 96.83 HENDLER SA, COHEN B, COLOMBEL J, S.. | 1 0.01 96.84 HENDLER SA, COHEN BL, COLOMBEL J, SAN.. | 1 0.01 96.85 HOEPNER, R., DAHLHAUS, S., KOLLAR, S... | 7 0.07 96.92 HOLSTEIN K, SCHNEPPENHEIM R, SCHRUM J.. | 1 0.01 96.93 HOLUB M, ARIENTOVA S, KORINKOVA M, RE.. | 1 0.01 96.94 IBA BA J, MOUNGUENGUI D, ELLA ONDO T... | 1 0.01 96.95 IDE M, UEMURA M, KAWACHI Y AND IZUMI .. | 1 0.01 96.96 IDE M, UEMURA M, KAWACHI Y AND IZUMI .. | 1 0.01 96.97 IDE M, UEMURA M, KAWACHI Y AND IZUMI .. | 1 0.01 96.98 IKEGAWA S, NAKASE K, KOHASHI S, AND M.. | 1 0.01 96.99 INOUE A, MAEMONDO M, SUGAWARA S, HARA.. | 1 0.01 97.00 IRIGOYEN AB, IRIDOY ZULET M. MUSICAL .. | 1 0.01 97.01 ISOBE Y, SUGIMOTO K, MASUDA A, HAMANO.. | 1 0.01 97.02 IWANAGA A, KIMURA N, HOMMA A, HORIGOM.. | 1 0.01 97.03 IWATA, T.. HEMATEMESIS FOLLOWING RAPI.. | 1 0.01 97.04 IWATSUBO S, TAKEDA S, KUMABE T, SUGAH.. | 1 0.01 97.05 J W PENDLETON ET AL.. DEMYELINATING D.. | 1 0.01 97.06 JABBOUR E, HAGOP K, THOMAS D, GARCIA-.. | 1 0.01 97.07 JACOBSEN RC. OUT-OF-HOSPITAL LINGUAL .. | 1 0.01 97.08 JATZKO A, SCHREINER A, BRAUS DF. AKUT.. | 1 0.01 97.09 JD H, BERENSON JR, LM K, A B, PJ R, S.. | 1 0.01 97.10 JITAWATANARAT P, KOSSOFF E, RIEBANDT .. | 1 0.01 97.11 JONVILLE-BERA A, VANDERMEER G, AZZOUZ.. | 1 0.01 97.12 JONVILLE-BERA A, VANDERMEER G, AZZOUZ.. | 1 0.01 97.13 JUILLERAT P, SOKOL H, YAJNIK V, FROEH.. | 1 0.01 97.14 KANESHIRO K. A CASE OF A PATIENT WITH.. | 1 0.01 97.15 KARAGEORGIOU CE, GIANNOULI E, GARIFAL.. | 1 0.01 97.16 KAUFMAN KR, PODOLSKY D, GREENMAN D, M.. | 1 0.01 97.17 KAUFMANN A, BOESCH S, FLEISCHHACKER W.. | 1 0.01 97.18 KAWAGUCHI K, MATSUBARA K, UCHIDA Y, S.. | 1 0.01 97.19 KEIL F, SELZER E, BERGHOLD A, RIEDL R.. | 1 0.01 97.20 KELLER MD. CD62L TEST EXPANDS NATALIZ.. | 1 0.01 97.21 KERN RM, SEETHAMRAJU H, BLANC PD, SIN.. | 1 0.01 97.22 KERVAN U., OZDAMAR Y., YURDAKOK O., K.. | 1 0.01 97.23 KIBLBOECK D, BRAEUER-MOCKER M, SIOSTR.. | 1 0.01 97.24 KIDA N, OTSURU T, TAKAESU K, FUKUJI Y.. | 1 0.01 97.25 KILLESTEIN J, VENNEGOOR A, VAN GOLDE .. | 1 0.01 97.26 KILONZO I; TWOMEY F.. ROTATING TO OR.. | 1 0.01 97.27 KIM S, HONG S, LIM Y, LEE J, KIM W, K.. | 1 0.01 97.28 KLAIN V, TIMMERMAN L. ANTIBIOMANIA, A.. | 1 0.01 97.29 KNAUSZ J, LIPTAK J, ANDRASOVSZKY Z, B.. | 1 0.01 97.30 KONDO H.. USE OF MOLECULAR TARGETED D.. | 1 0.01 97.31 KONJETI V.R., PALURI S.. DISSEMINATED.. | 1 0.01 97.32 KOPAC P, ZIDARN M, BAJROVIC N, MUSIC .. | 1 0.01 97.33 KOSKINAS J, TAMPAKI M, DOUMBA PP, RAL.. | 1 0.01 97.34 KRISTA J M S, HAJO I J W, PIETERNELLA.. | 1 0.01 97.35 KRYSIAK R, OKOPIEN B. DRUG-INDUCED EX.. | 1 0.01 97.36 KURAHASHI H.. A CASE OF CARDIAC METAS.. | 1 0.01 97.37 KWOK WC, CHAN TC, LUK J, CHAN F. METF.. | 1 0.01 97.38 LANKISCH P, LAWS HJ, WINGEN AM, BORKH.. | 1 0.01 97.39 LASIC D, IVANISEVIC R, UGLESIC B, CVI.. | 1 0.01 97.40 LAURITSEN L, SAHL C, THORSEN S.. NEBU.. | 1 0.01 97.41 LE POLGREEN, NA KARRAS, E LIPSITZ, ET.. | 1 0.01 97.42 LEEAMORNSIRI S, CHOOPONG P, TESAVIBUL.. | 1 0.01 97.43 LEHMANN T, HOFER KE, BAUMANN M, HASLE.. | 1 0.01 97.44 LENFESTEY A, FRIEDMANN D, BURKE WA. M.. | 1 0.01 97.45 LEOZ MK, CONCEJO FB, FERNANDEZ JMU, U.. | 1 0.01 97.46 LEPPA S, TARKKANEN M. RADIOLOGIC SIDE.. | 1 0.01 97.47 LESIAK A, WLODARCZYK M, SOBOLEWSKA A,.. | 1 0.01 97.48 LETMAIER M, PAINOLD A, HOLL AK, GROHM.. | 1 0.01 97.49 LI HONGWU. THREE CASES OF PLATELETS D.. | 3 0.03 97.52 LIANG XIAOLI. THROMBOCYTOPENIA DUE TO.. | 1 0.01 97.53 LIM D, RADEMAKER M, ASZTELY F, RATNAW.. | 1 0.01 97.54 LIM MH, PARK J-I, PARK TW. A CASE WIT.. | 1 0.01 97.55 LING S. A CASE OF LIVER DYSFUNCTION C.. | 1 0.01 97.56 LIPTAK J, SCHNOPP C, RING J, ANDRES C.. | 1 0.01 97.57 LIU Z, WILLIAMS RB, ROSEN BD. THE POT.. | 1 0.01 97.58 LORIO ML, CHEERHARAN M, KAUFMAN SS, R.. | 1 0.01 97.59 LOW L, ZAHERI S, WAKELIN S. AMLODIPIN.. | 1 0.01 97.60 MABUCHI S, YOSHIKAWA K, TAKAHASHI H, .. | 1 0.01 97.61 MABUCHI, S. A CASE OF CALCIUM CHANNEL.. | 1 0.01 97.62 MACHIELS JP. ACUTE ARDIAC FAILURE AFT.. | 1 0.01 97.63 MANSO G,JIMENO F,ORDONEZ L,SALGUEIRO .. | 1 0.01 97.64 MARGAREETA H?KKINEN. PROFILES OF PREG.. | 1 0.01 97.65 MARGOLES HR, GOMEZ-LOBO V, VEIS JH, S.. | 1 0.01 97.66 MARIA GOMEZ-GALLEGO. MULTIPLE SCLEROS.. | 1 0.01 97.67 MARKS S, HEINRICH TW, ROSIELLE D. CAS.. | 1 0.01 97.68 MARONAS-JIMENEZ L. ACRAL EROSIONS AND.. | 1 0.01 97.69 MARTI G, RIO J, ROVIRA A, AUGER C, TI.. | 1 0.01 97.70 MASANORI MIZUNO ET AL.,. STARTING FIN.. | 1 0.01 97.71 MATHILDE L. HEPATITIS AFTER RETINOID .. | 1 0.01 97.72 MATSUNO R, TOYAMA D, FUJITA S, HANAMU.. | 2 0.02 97.74 MATSUNO R, TOYAMA D, FUJITA S, HANAMU.. | 1 0.01 97.75 MATSUZAKI H,KOGA Y,SUMINOE A,OBA U,TA.. | 1 0.01 97.76 MAVIKI M, COWLEY P, MARMERY H. INJECT.. | 2 0.02 97.78 MAVRI A,STALC M. DABIGATRAN IN RIVARO.. | 5 0.05 97.83 MCGREGOR AK, LAIGHT NS, NOLAN S. PARA.. | 1 0.01 97.84 MCINTYRE, I.M.. HYDROXYZINE DISTRIBUT.. | 1 0.01 97.85 MICHAEL C. KRUER. INFLAMMATORY NEUROL.. | 1 0.01 97.86 MIKA TAKASUMI. A CASE OF METHOTREXATE.. | 1 0.01 97.87 MILAT F, WONG P, FULLER P, JOHNSTONE .. | 1 0.01 97.88 MILLER BT, LEWIS C, BENTZ BG. BLACK T.. | 1 0.01 97.89 MINORU NAKANE ET AL.. EXPERIENCE OF T.. | 1 0.01 97.90 MITCHELL SNYDER. SERTRALINE-INDUCED R.. | 1 0.01 97.91 MITTAL, K. DUAL VEGF/VEGFR INHIBITION.. | 1 0.01 97.92 MITTAL, K.. DUAL VEGF/VEGFR INHIBITIO.. | 1 0.01 97.93 MIZUNO R, ASANO K, MIKAMI S, NAGATA H.. | 1 0.01 97.94 MODI D, DUBOVY SR. NON-LEAKING CYSTOI.. | 1 0.01 97.95 MONTALVAO A. USE OF BORTEZOMIB (VELCA.. | 2 0.02 97.97 MONTALVAO A. USE OF BORTEZOMIB (VELCA.. | 1 0.01 97.98 MOORE PW, DONOVAN JW, BURKHART KK, HA.. | 1 0.01 97.99 MOORE PW, DONOVAN JW, BURKHART KK, HA.. | 1 0.01 98.00 MORGAN MD, DRAYSON MT, SAVAGE CO, HAR.. | 1 0.01 98.01 MORGAN MD, DRAYSON MT, SAVAGE CO, HAR.. | 1 0.01 98.02 MORITA, TOMOHIRO ET AL.. A CASE OF MA.. | 1 0.01 98.03 MORIWAKA O, ET AL.,. THE JOURNAL OF J.. | 1 0.01 98.04 MOSS H, COLLIER JM, COLLIER S. AN UNU.. | 1 0.01 98.05 MOU SS, PUNARO L, ANTON J, LUCKETT PM.. | 1 0.01 98.06 MUNST A, HARTMANN K, DEAK C, CAPONE M.. | 1 0.01 98.07 MUTO S, KAWANO H, NAKATOMI D, YAMASA .. | 1 0.01 98.08 M^KADA H, PERAZZO H, MUNTEANU M, NGO .. | 1 0.01 98.09 NAGATOMO, YASUSHI. A CASE REPORT OF G.. | 1 0.01 98.10 NAKAMURA S,MIYASHITA T,HAYASHI H,TAJI.. | 1 0.01 98.11 NAKAYAMA C. A CASE OF PSORIATIC ONYCH.. | 1 0.01 98.12 NATALIZUMAB RELATED PML: ATYPICAL NE.. | 1 0.01 98.13 NELSON H, KATZ D, DUNN T, SINGH G, VO.. | 1 0.01 98.14 NGAMRUENGPHONG S, ZHAI Q, FRANCIS D. .. | 1 0.01 98.15 NIKOLATOU GALITIS ET AL. GINGIVAL BLE.. | 1 0.01 98.16 NISHIMURA H, FURUMIYA J, NAKANISHI A,.. | 1 0.01 98.17 NISHIMURA K, OMORI M, SATO E, KATSUMA.. | 5 0.05 98.22 NITYA S, DEEPA K, MANGAIARKKARASI A, .. | 1 0.01 98.23 NOBUYASU AWANO. THE 113RD GENERAL AND.. | 1 0.01 98.24 NORDGAARD, J.. PREGABALIN CAN CAUSE A.. | 1 0.01 98.25 NORTHOVER JR, WILLIAMSON D, ROOKER J,.. | 1 0.01 98.26 NOSAL M,BATOROVA A,JANKOVICOVA D,SOPK.. | 1 0.01 98.27 OKA Y, MATSUDA NORIYA, IKEDA MASAKI, .. | 1 0.01 98.28 OKRUSZKO A, BARAN A, ZWIERZ-GUGALA D,.. | 1 0.01 98.29 OREGEL KZ, RAMDIAL J, GLUCK S. NONST.. | 1 0.01 98.30 ORTEGA-LOAYZA AG, MCCALL CO, COOKE RH.. | 1 0.01 98.31 PADALA PR, PADALA KP, MONGA V, RAMIRE.. | 1 0.01 98.32 PADALA PR, PADALA KP, MONGA V, RAMIRE.. | 1 0.01 98.33 PALUNGWACHIRA P, PALUNGWACHIRA P, OGA.. | 1 0.01 98.34 PATEL M K, BRUNETTI L. NEUROLEPTIC MA.. | 1 0.01 98.35 PAULEY KA, SANDRITTER T, LOWRY J, ALG.. | 1 0.01 98.36 PENDLETON JW. DEMYELINATING DISEASE A.. | 1 0.01 98.37 POGLIANI L, MAMELI C, CATTANEO D, CLE.. | 1 0.01 98.38 PROTIC M, SEIBOLD F, SCHOEPFER A, RAD.. | 1 0.01 98.39 PUNIA, V.. STROKE AFTER INITIATING IV.. | 1 0.01 98.40 R D GRANSTEIN. ETANERCEPT AND DEMYELI.. | 1 0.01 98.41 RASCHI E,POLLUZZI E,KOCI A,SALVO F,PA.. | 1 0.01 98.42 RASCHI E,POLUZZI E,KOCI A,SALVI F,PAR.. | 1 0.01 98.43 RASCHI E,POLUZZI E,KOCI A,SALVO F,PAR.. | 1 0.01 98.44 RASCHI E,POLUZZI E,KOCI A,SALVO F,PAR.. | 31 0.31 98.75 RASCHI E,POLUZZI E,KOCI A,SALVO S,PAR.. | 1 0.01 98.76 RAUBER-LUTHY C, HOFER KE, BODMER M, K.. | 1 0.01 98.77 REPORTER KNOWN TO HEALTH AUTHORITY. U.. | 1 0.01 98.78 RINI B, BELLMUNT J, KORALEWSKI P, MAH.. | 1 0.01 98.79 RIVERA F, MASSUTI B, SALCEDO M, SASTR.. | 1 0.01 98.80 RIVINIUS R, HELMSCHROTT M, RUHPARWAR .. | 1 0.01 98.81 RIZOS E, TSIGKAROPOULOU E, LAMBROU P,.. | 1 0.01 98.82 RIZZO R, GULISANO M, CALI PV. OCULOGY.. | 1 0.01 98.83 ROCCO A, LOGGINI A, ROCCO M, ROCCO P,.. | 1 0.01 98.84 RODRIGUES-SILVA N, VENANCIO A, BOUCA .. | 1 0.01 98.85 ROHRS S, GEISER F, CONRAD R. CITALOPR.. | 1 0.01 98.86 ROMANO M, ZORZOLI F, BERTONA R, VILLA.. | 1 0.01 98.87 ROWE CJ, ROBERTSON I, JAMES D, MCMENI.. | 1 0.01 98.88 SABIN MG, ALVAREZ AM, CAPDEVILA EF, C.. | 1 0.01 98.89 SAGAWA N, ET AL.. A CASE OF ACICLOVIR.. | 1 0.01 98.90 SAKAI YOSHIRO, ET AL.. POTENTIAL DRUG.. | 2 0.02 98.92 SAKAI YOSHIRO, ET AL.. POTENTIAL DRUG.. | 1 0.01 98.93 SAKAI YOSHIRO. POTENTIAL DRUG INTERAC.. | 1 0.01 98.94 SANCHEZ, R.. SEVERE DECREASE OF CYCLO.. | 1 0.01 98.95 SANTOS M, SILVA J, POLIDO-PEREIRA J, .. | 1 0.01 98.96 SARICI D, AKIN MA, KURTOGLU S, UZUM K.. | 1 0.01 98.97 SARLON J, HESS E, KRASNIANSKI A. VALP.. | 1 0.01 98.98 SATO Y, KUWASHIMA S, KUROSAWA H, SUGI.. | 1 0.01 98.99 SCHILLER D, SCHOEFL R, HOLZMANN H. FA.. | 1 0.01 99.00 SEIBERT JB, ALVAREZ E. SEVERE ANEMIA .. | 1 0.01 99.01 SEIDEL R.. SUCCESSFUL USE OF C1 ESTER.. | 1 0.01 99.02 SHIGEFUKU R, IKEDA HIROKI, HARA MASAK.. | 1 0.01 99.03 SHIGEKI MITSUOKA ET AL.. THREE SERIOU.. | 1 0.01 99.04 SHIMIZU Y. HOW TO MANAGE MEDICAL TREA.. | 2 0.02 99.06 SHIMIZU Y. HOW TO MANAGE MEDICAL TREA.. | 1 0.01 99.07 SHINKAI RI ET AL.. A CASE OF RHEUMATO.. | 1 0.01 99.08 SHIOZAWA P, ENOKIBARA DA SILVA M, COR.. | 1 0.01 99.09 SHOUSHTARI AH, SHAW RA.. FULMINANT HE.. | 1 0.01 99.10 SILVA R, BOTELHO C, CADINHA S, LISBOA.. | 1 0.01 99.11 SIN C, GIRARD C, SIGAL ML, MAHE E. TW.. | 1 0.01 99.12 SKOURIDES D, SAMARTZIS L.. INITIATION.. | 1 0.01 99.13 SMETANA M, PICARD K, BOEHM K. AN ACUT.. | 1 0.01 99.14 SOCINSKI M. A.. MULTICENTER, PHASE II.. | 1 0.01 99.15 SOCINSKI M.A.. MULTICENTER, PHASE II .. | 1 0.01 99.16 SOETENS F, ROSE M, FISHER M. TIMING O.. | 1 0.01 99.17 SOUFRAS, G. ADRENALINE ADMINISTRATION.. | 1 0.01 99.18 SRIRAM A, WARD HE, HASSAN A, IYER S, .. | 1 0.01 99.19 STENZEL J, RUHNAU L, EINW?CHTER H, FE.. | 2 0.02 99.21 STOEBNER PE, MICHOT C, LIGERON C, DUR.. | 1 0.01 99.22 STORK, L., BRUCK, W., BAR-OR, A. + ME.. | 3 0.03 99.25 STORRIER S, BERAN RG. COMPULSIVE GAMB.. | 1 0.01 99.26 SWERLICK RA, CAMPBELL CF. MEDICATION .. | 1 0.01 99.27 TADAHIRO ISOYAMA ET AL.. A CASE OF AD.. | 1 0.01 99.28 TAGUCHI Y, TAKASHIMA S AND TANAKA K. .. | 1 0.01 99.29 TAKAFUJI S, KAWASAKI K, NINO N, YOKOI.. | 1 0.01 99.30 TAKAHASHI T, TAKAHASHI T, SUZUKI E, K.. | 1 0.01 99.31 TAKESHI KATSUMOTO. TWO CASES OF CYSTO.. | 1 0.01 99.32 TANAKA, T.. ONSET OF PUBERTY AND NEAR.. | 1 0.01 99.33 TANIGUCHI G, MIYAJIMA M, WATANABE M, .. | 1 0.01 99.34 TANIGUCHI. NONCONVULSIVE STATUS EPILE.. | 1 0.01 99.35 TATSUYA TAKAYAMA, ET AL.. INAPPROPRIA.. | 1 0.01 99.36 THERAPEUTIC GOODS ADMINISTRATION. MET.. | 1 0.01 99.37 TIAN R, ZHAO G CEFTRIAXONE INDUCED DR.. | 1 0.01 99.38 TIMOTHY, E.. TRANSFUSION-ASSOCIATED G.. | 1 0.01 99.39 TOMIC S, BUTKOVIC-SOLDO S, MIROSEVIC-.. | 1 0.01 99.40 TOMINAGA, T.. A CASE OF HEART FAILURE.. | 1 0.01 99.41 TOMOYUKI O, KEIJI I, NANAKO T, ANNA T.. | 1 0.01 99.42 TOPAL IO. DYSPAREUNIA AND VAGINAL BLE.. | 1 0.01 99.43 TOSHIYUKI KATAOKA, ET AL.. A CASE OF .. | 1 0.01 99.44 TOYOWAKA T, MUGURUMA K, TANAKA H, SHI.. | 1 0.01 99.45 TRIMARCHI H, GONZALEZ J, OLIVERO J. H.. | 1 0.01 99.46 TRINKAUS M.. DRUG-INDUCED IMMUNE THRO.. | 1 0.01 99.47 TSUNEMORI HIROYUKI. A TREATMENT EXPER.. | 1 0.01 99.48 TURAN H, GURLEVIK Z, YANIK ME, BALBAY.. | 1 0.01 99.49 TUREGANO, MAMINA. ULCERATION OF PRE-E.. | 1 0.01 99.50 UCHINO T, MISHIMA H, KIMURA K, MORI D.. | 1 0.01 99.51 UNKNOWN. FATAL GROUP A STREPTOCOCCUS .. | 1 0.01 99.52 UTSUMI S,KANNO T,OOTOMO M. A CASE OF .. | 1 0.01 99.53 VAN DRIE CE, KUYPERS MI. A MAN WITH E.. | 1 0.01 99.54 VEIBY G, DALTVEIT AK, ENGELSEN BA, GI.. | 1 0.01 99.55 VELASCO-MONTES J, ORINUELA-GONZALEZ I.. | 1 0.01 99.56 VENNEGOOR A, VAN ROSSUM J A, POLMAN C.. | 3 0.03 99.59 VILLAR LM, COSTA-FROSSARD L, MASTERMA.. | 1 0.01 99.60 VINETTI M, DUPREZ T, HANTSON P. SEVER.. | 1 0.01 99.61 VISSCHER A.J.E, COHEN D.. PERIORBITAL.. | 1 0.01 99.62 VYAS VH, MOHITE SN, KHATAVKAR SS, JAG.. | 1 0.01 99.63 W XU, MJ PEDRINI, J BURTON, WM CARROL.. | 1 0.01 99.64 WAGNER SN, WELKE F, GOOS M. OCCUPATIO.. | 1 0.01 99.65 WASS, M. CRIZOTINIB IN ALK-POSITIVE D.. | 1 0.01 99.66 WESTERBERGH J, HOJER J. METFORMIN-IND.. | 1 0.01 99.67 WIEGAND TJ, WAX PM, SCHWARTZ T, FINKE.. | 12 0.12 99.79 WIELEMA ML, DE GRAAF H, DE GROOT J, P.. | 2 0.02 99.81 WIGLUSZ MS, CUBALA WJ, NOWAK P, JAKUS.. | 1 0.01 99.82 WILLIAMS GS, GOODWIN R, HUGHES D. AML.. | 1 0.01 99.83 WINTHROP, KEVIN L.. HERPES ZOSTER AND.. | 1 0.01 99.84 WINTHROP. HERPES ZOSTER AND TOFACITIN.. | 1 0.01 99.85 WOOL G. B-LYMPHOBLASTIC LEUKEMIA IN P.. | 1 0.01 99.86 WOOL G. B-LYMPHOBLASTIC LEUKEMIA IN P.. | 1 0.01 99.87 WORTMANN DW, KELSCH RC, KUHNS L, SULL.. | 1 0.01 99.88 YALBUZDAG SA, CELIK C, YEGIN T. ISOTR.. | 1 0.01 99.89 YAMAN A, KENDIRLI T, ODEK C, BEKTAS O.. | 1 0.01 99.90 YAMANISHI W, TANABE YUJIRO, AKAHANE Y.. | 1 0.01 99.91 YANG BL, LIN Q, CHEN HJ, SUN GD, ZHU .. | 1 0.01 99.92 YANG XIAOQING. ANAPHYLACTIC SHOCK AND.. | 1 0.01 99.93 YASUHARA T. YL0007061: 1-2-46 TWO CAS.. | 1 0.01 99.94 YILMAZER B, COSAN F, CEFLE A. BILATER.. | 1 0.01 99.95 ZAKARY N, ELSHEIKH A, HAMID N, ABDULA.. | 1 0.01 99.96 ZILKER T. OCCURRENCE OF POISONING OVE.. | 1 0.01 99.97 ZIMRAN, A.. SAFETY AND EFFICACY OF TW.. | 1 0.01 99.98 ZUBONYAI C, BATTYANI Z, KOLLAR B, EGY.. | 1 0.01 99.99 [INANLI I, ETLI T, OZTURK HI, EREN I,.. | 1 0.01 100.00 ----------------------------------------+----------------------------------- Total | 10,000 100.00 by Jean Roth , jroth@nber.org , 6 Apr 2017